NovAccel Begins Taking Sample Sales Reservations for 'Actinium-225'

NovAccel Inc. (Headquarters: Ibaraki Prefecture, hereinafter 'NovAccel'), which develops the proprietary compact superconducting accelerator RiSA aiming to manufacture medical radioisotopes, is pleased to announce that, accompanying the operation of its manufacturing base within Hiroshima University, it will start a sample supply program for the medical radioisotope 'Actinium-225' around the fourth quarter of 2026. This isotope is essential for next-generation cancer treatment (Targeted Alpha Therapy: TAT) and targets medical institutions, pharmaceutical companies, and research institutions.

■ 'High Quality and Stable Supply' Realized by NovAccel

Our manufacturing method using a superconducting electron linear accelerator solves the geopolitical risks and impurity issues associated with conventional manufacturing methods, realizing high quality with a radionuclide purity of over 99.99%. Furthermore, after the start of operations, we will gradually increase the manufacturing volume to establish a stable supply system.

■ Operation of Manufacturing Facilities at Hiroshima University to Begin in 2026, Sample Supply Scheduled to Start

Under a strong industry-academia partnership with Hiroshima University, the first RiSA unit and the chemical facilities for extracting 'Actinium-225' are scheduled to enter full-scale operation in Building F3 on the university's Higashi-Hiroshima Campus. Along with this, we will begin the sample supply.

Estimated Supply Volume: Anticipated to be 100 to 300 MBq per month (Total over the period: approx. 1 GBq)

■ 'Three Sample Supply Plans' Responding to Diverse Development Needs

Prior to the start of supply, we will begin accepting reservations and inquiries from today under the following three plans.

Strategic Partner Plan:
[Target: Pharmaceutical Companies]
A partnership plan that allows for individual specification consultations and customization with an eye toward future continuous supply.

Spot Reserve Plan:
[Target: Universities and Research Institutions]
A single-time (spot) provision plan tailored to specific projects or research applications.

Evaluation Sample Plan:
[Target: Small-scale evaluation and testing]
A trial provision plan in a simplified package for quality confirmation and initial evaluation.

■ Supply Vision Supporting the Future of Cancer Treatment: Toward Establishing a Mass Production System in 2028

'Providing necessary treatment, when needed, to all patients' —

Under this mission, we will start commercial delivery in April 2027 and strengthen our system toward mass production at our own factory in 2028. Starting with the launch of supply in Hiroshima, we will build a stable supply system that strongly supports the foundation of next-generation cancer treatment.

[Inquiries and Sample Reservations Regarding This Matter]

Inquiries regarding detailed supply conditions and joint research are accepted at the following:

Email: info@novaccel.jp

[Corporate Information]

NovAccel Inc.
(Headquarters) 3706-1 Mushikake, Tsuchiura City, Ibaraki Prefecture
Official Website: https://novaccel.jp/